Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.
about
Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Identification and mutagenesis of the adeno-associated virus 5 sialic acid binding region.Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8.Strategies to circumvent humoral immunity to adeno-associated viral vectors.Capsid antibodies to different adeno-associated virus serotypes bind common regions.An emerging adeno-associated viral vector pipeline for cardiac gene therapyMapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery VectorsPre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors.New and improved AAVenues: current status of hemophilia B gene therapy.Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding SiteStructure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion.Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies.Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resinAdeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.Strategy to detect pre-existing immunity to AAV gene therapy.Cre Recombinase Mediates the Removal of Bacterial Backbone to Efficiently Generate rSV40.Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles.Parvoviruses: structure and infection
P2860
Q34370111-8E21C097-2EE2-455C-AE96-C37F11434530Q34991472-35E92A6C-02F8-47DD-986C-3ADD5ABCC9BEQ36171849-4B80537C-F0AE-4713-B73B-4E9EA4209098Q36398678-5E05845F-DCB9-4B45-89A8-896824932241Q37123344-97599AE0-A0E4-4789-86DF-A372536C53ADQ37272838-7025DD4C-ED7A-4FBA-ADC0-A7C2B44EABDDQ38187651-2BD7642C-BF7F-42A5-93E9-636A0FE2B312Q38191212-E323E25A-AF04-445D-AFC2-469CD2B42EEBQ38622440-920B282D-A9E5-45A6-9FDE-995222F73913Q38787435-E7114530-A6C6-4CB2-B3CE-6BB7E167ABFAQ40180004-07BBA108-F15F-42EF-9D0B-F57A760919B0Q40611143-D7E78DDD-247B-490F-BF25-64140FB71D20Q41025401-2761CCDC-E9C8-42AF-9056-ED276B912705Q41098235-D3843BB3-AB5F-49D5-B58D-8AB11AF13708Q41606960-CB4542D9-C27A-4322-BECF-A00D7095852DQ45874009-BFF6CCB4-4227-4430-9152-5313024EB91EQ54210508-089C7C7E-31CA-40D6-B119-1801E79014A0Q55286992-45FEE808-3270-4CDC-A841-0DF7132422AAQ56115905-51636894-DE9E-458F-A346-D1062CE49DB6
P2860
Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Examining the cross-reactivity ...... iated virus serotypes 1 and 5.
@ast
Examining the cross-reactivity ...... iated virus serotypes 1 and 5.
@en
type
label
Examining the cross-reactivity ...... iated virus serotypes 1 and 5.
@ast
Examining the cross-reactivity ...... iated virus serotypes 1 and 5.
@en
prefLabel
Examining the cross-reactivity ...... iated virus serotypes 1 and 5.
@ast
Examining the cross-reactivity ...... iated virus serotypes 1 and 5.
@en
P2093
P2860
P356
P1476
Examining the cross-reactivity ...... iated virus serotypes 1 and 5.
@en
P2093
Brittney L Gurda
Carole E Harbison
Colin R Parrish
John A Chiorini
Wendy S Weichert
P2860
P304
P356
10.1099/VIR.0.035113-0
P407
P577
2011-11-09T00:00:00Z